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ABSTRACT Objective: Vitamin D receptor (VDR) mediates vitamin D activity. We examined whether VDR expression in excised melanoma
tissues is associated with VDR gene (VDR) polymorphisms.
Methods: We evaluated VDR protein expression (by monoclonal antibody immunostaining), melanoma characteristics, and
carriage of VDR-FokI-rs2228570 (C>T), VDR-BsmI-rs1544410 (G>A), VDR-ApaI-rs7975232 (T>G), and VDR-TaqI-rs731236
(T>C) polymorphisms (by restriction fragment length polymorphism). Absence or presence of restriction site was denoted by a
capital or lower letter, respectively: “F” and “f” for FokI, “B” and “b” for BsmI, “A” and “a” for ApaI, and “T” and “t” for TaqI
endonuclease. Seventy-four Italian cutaneous primary melanomas (52.1±12.7 years old) were studied; 51.4% were stage I, 21.6%
stage II, 13.5% stage III, and 13.5% stage IV melanomas. VDR expression was categorized as follows: 100% positive vs. <100%;
over the median 20% (high VDR expression) vs. ≤20% (low VDR expression); absence vs. presence of VDR-expressing cells.
Results:  Stage I melanomas, Breslow thickness of <1.00 mm, level II Clark invasion, Aa heterozygous genotype, and AaTT
combined genotype were more frequent in melanomas with high vs. low VDR expression. Combined genotypes BbAA, bbAa,
AATt, BbAATt, and bbAaTT were more frequent in 100% vs. <100% VDR-expressing cells. Combined genotype AATT was more
frequent in melanomas lacking VDR expression (odds ratio=14.5; P=0.025). VDR expression was not associated with metastasis,
ulceration, mitosis >1, regression, tumor-infiltrating lymphocytes, tumoral infiltration of vascular tissues, additional skin and
non-skin cancers, and melanoma familiarity.
Conclusions:  We highlighted that  VDR  polymorphisms can affect  VDR expression in  excised melanoma cells.  Low VDR
expression in AATT carriers is a new finding that merits further study. VDR expression possibly poses implications for vitamin D
supplementation against melanoma. VDR expression and VDR genotype may become precise medicinal tools for melanoma in the
future.
KEYWORDS Vitamin D receptor; VDR protein expression; VDR polymorphism; cutaneous melanoma; metastatic melanoma; skin cancer;
predictive biomarkers; FokI polymorphism
 
Introduction
Cutaneous melanoma incidence continually increases in deve-
loped  countries,  particularly  in  fair-skinned  individuals1-4.
Recent  data5  indicated  that  prevalence  of  melanoma  in
Northern Italy is  two fold higher than in Southern Italy and
with  Central  Italy  showing  prevalence  at  intermediate  level.
High  incidence  rates  were  particularly  registered  in  the
Northeast  Friuli-Venezia Giulia region (19.6/100,000/year in
men;  16.4/100,000/year  in  women)6,  implying  that  geogra-
phically  detailed  studies  should  be  performed  regarding
melanoma risk factors7.
Melanoma is the leading cause of mortality among skin
cancer  patients  with  low  survival  rates8.  Although  new
therapeutic  treatments  are  available9,  early  detection and
surgery remain the main treatment options. Therefore, every
new discovery on melanoma biological pathways presents
opportunity  in  improving  management  and  treatment
options.  Considerable  preclinical  and epidemiologic  data
suggest that vitamin D may play an important role in cancer
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pathogenesis  and  progression10.  Numerous  preclinical
studies specifically indicated that exposure of cancer cells to
high  concentrations  of  vitamin  D  metabolites  halts  pro-
gression through the cell cycle, induces apoptosis, and slows
down or  stops tumor growth11.  Vitamin D also enhances
antitumor activity of some cytotoxic anticancer agents in in
vivo preclinical models12. Anti-proliferative effects of vitamin
D for  cancer  prevention  and treatment  were  explored  in
several  malignancies,  including  skin,  breast,  prostate,
colorectal,  and  other  cancers8,13-18 .  Numerous  epi-
demiological  studies  supported  the  hypothesis  that
individuals with lower serum vitamin D levels feature higher
exposure  risk  to  different  cancers12.  Current  literature
suggests the chemopreventive role of vitamin D by acting
against  initiation and progression of  tumorigenesis8,12-18.
Despite the stronger consensus on protective role of vitamin
D against cancer, particularly by reduction of mortality rate,
its  therapeutic  function  for  cancer  patients  remains
debatable10,19.  Remarkably, a recent meta-analysis showed
that  vitamin  D  supplementation  minimally  affects  total
cancer  incidence,  even  when  total  cancer  mortality  is
significantly reduced20.
Vitamin D receptor (VDR) is a nuclear transcription factor
belonging to the nuclear receptor superfamily that binds 1α,
25-dihydroxyvitamin D (calcitriol)  with high affinity and
specificity19. Upon binding to the active form of vitamin D,
VDR translocates from cytoplasm into the nucleus and binds
to  vitamin  D  responsive  elements  (VDREs),  thus  up-  or
down-regulating hundreds of genes directly controlled by
vitamin D19,21,22.  Increasing  evidence  showed pleiotropic
hormonal  effects  of  vitamin  D  on  calcium  and  skeletal
metabolism,  immunological  responses,  detoxification,
oxidative  stress,  cancer-related  metabolic  pathways,
proliferation, and cell differentiation18,19,21.
VDR is abundantly expressed in the skin19,21. Some VDR
expression was also reported to occur in cultured melanoma
cells11,13,14,23. Intermittent sun exposure or ultraviolet (UV)
radiation and sunburns are known environmental risk factors
for melanoma24,25.  However,  chronic and continuous UV
radiation exposure activates vitamin D biosynthesis, which in
turn  can  develop  a  protective  action  against  tumoral
proliferation8,12,16,25. Four recently discovered mechanisms
may underlie actions of VDR as a tumor suppressor in the
skin10.
Human VDR gene is located on chromosome 12q12-q14
and comprises 11 exons and 11 introns26. Genetic variants of
VDR may modulate its actions, with FokI, BsmI, ApaI, and
TaqI  be ing  the  most  s tudied  s ing le-nuc leot ide
polymorphisms (SNPs)26-28. VDR-FokI polymorphism is a
functional SNP that extends lengths of the receptor protein
from 424 to 427 amino acid residues. BsmI, ApaI, and TaqI
polymorphisms are located in the 3′ terminal region of the
VDR  gene and do not affect protein sequence of the VDR
receptor. FokI polymorphism is reported not to be in linkage
disequilibrium with the other three polymorphisms. Instead,
BsmI, ApaI, and TaqI polymorphisms are reported to be in
linkage disequilibrium to a variable extent; thus, combined
genotypes including two or three of these polymorphisms
were  investigated  in  literature26,28,29.  Some  evidence
suggested  that  genotypes  FF,  BB,  tt,  and  the  combined
genotype  BBAAtt  may  be  associated  with  increased
expression  of  VDR,  which  in  turn  regulates  actions  of
vitamin D26-28. Roles of VDR polymorphisms in melanoma
were evaluated in some recent studies and meta-analyses30-37.
However,  associations  of  VDR  polymorphisms  with  skin
cancer risk remain insufficiently characterized30,31,36.
At present, no study examined VDR polymorphisms and
VDR expression in melanoma cells of excised tissues from
patients.
Thus far, only one cohort of 69 Polish melanoma patients
was investigated by two studies for VDR expression in tumor
tissues38,39.  VDR expression progressively  decreases  from
normal skin to melanocytic nevi to melanomas38, suggesting
the relationship between VDR expression and melanoma
prognosis39.  Brożyna  and  colleagues38  observed  reduced
expression  levels  of  VDR  in  skin  surrounding  nevi  and
melanomas as opposed to normal skin.
Advances in melanoma treatment can be achieved through
developments in understanding of melanoma risk factors,
genomics, and molecular pathogenesis31,40.
By immunohistochemical staining of primary cutaneous
melanoma  tissues,  we  investigated  VDR  expression  in
relation to characteristics,  melanoma histological grading,
and  metastatic  stage  of  patients.  We  also  explored  the
association of four VDR SNPs- FokI-rs2228570 C>T located
in exon 2, BsmI-rs1544410 G>A located in intron 8, ApaI-
rs7975232 T>G located in intron 8, and TaqI-rs731236 T>C
located in exon 9- with VDR expression levels in cutaneous
malignant melanoma tissues.
Patients and methods
Patients
Enrolment  and  clinical  visits  of  all  study  participants  were
performed  at  the  Udine  University-Hospital  Dermatology
Clinic.  Diagnostic  procedures  were  conducted  according  to
routine protocols. All participants signed a written informed
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consent.  The  Udine  Institutional  Ethical  Committee  app-
roved the study protocol in accordance to the Declaration of
Helsinki.
Seventy-four (39 males, 35 females, age range: 29-82 years)
unrelated  patients  (hospitalized  or  outpatients)  who
consecutively  underwent  surgical  excision  of  cutaneous
melanoma were enrolled based on a  retrospective  design.
Inclusion criteria were as follows: melanoma different from
that in in situ only, absence of mucosal melanomas, patient is
a resident of Friuli-Venezia Giulia region (Northern Italy),
and absence of major chronic diseases, such as autoimmune
diseases, and type 1 diabetes.
Assessment  of  melanoma  diagnosis  and  patient  stage
classification were performed by clinical/histological findings
as  described  by  Balch  et  al.41.  For  patients  with  multiple
melanomas,  we  examined  only  the  first  main  melanoma
according to histological assessment of major primary tumor
grading,  and  primary  melanoma  characteristics  were
accounted for study analyses.
Questionnaires were used to collect information from each
participant; data obtained included demographic and lifestyle
characteristics and medical and family history of melanoma.
Body mass index (BMI) was determined by ratio of weight
(kg) to squared height (m).
Immunohistochemical staining and evaluation
of VDR expression
Slides stained with hematoxylin and eosin were reviewed for
each case from formalin-fixed and paraffin-embedded blocks
and  were  selected  for  VDR  immunohistochemical  staining.
Immunohistochemistry  was  performed  on  5  µm  thick
paraffin sections as  follows:  after  dewaxing,  rehydration and
endogenous  peroxidase  quenching  with  3%  v/v  H2O2  in
methanol  for  15  min,  antigen  retrieval  in  0.01  M  citrate
buffer  at  98°C  water  bath  for  40  min,  application  and
incubation of primary antibody (VDR mouse monoclonal D-
6, sc-13133, Santa Cruz Biotechnology, Texas, USA) at 1:200
dilution  1  h  at  room  temperature42,43,  incubation  with
peroxidase-based EnVision+ /Horseradish peroxidase  (Dako
A/S,  Glostrup,  Denmark)  for  30  min  at  room  temperature,
and  treatment  with  diaminobenzidine  for  3  min44.  The
sections were then counterstained with Mayer’s hematoxylin,
dehydrated, and mounted. VDR expression was evaluated on
tumor  cells  (nuclear  and  cytoplasmic  staining)  of  the  whole
section.  Immunolabeled  sections  were  viewed  under  Nikon
Eclipse  80i  light  microscope  at  25×  magnification,  and  a
semi-quantitative  evaluation  was  performed  to  determine
VDR expression levels in malignant melanoma cells (nuclear
and  cytoplasmic  staining).  Staining  of  sweat  gland  cells,
which  consistently  showed  strong  and  diffused  positivity
throughout  all  samples,  was  used  as  positive  reference.  The
term  “emboli”  indicates  tumoral  invasion  of  vascular  cells
observed  in  slide  specimens.  Melanoma  specimens  were
reviewed by two pathologists  involved in the study but were
unaware  of  all  other  clinical  and  molecular  data  during
evaluation.  Our  categorization  choices  were  based  on  the
following considerations:  A) when melanomas feature 100%
VDR-positive cells,  all  tumor cells are possibly responsive to
vitamin  D  stimulation;  B)  when  0%  cells  are  positive  for
VDR  expression,  virtually  all  tumor  cells  do  not  respond  to
vitamin  D stimulation;  C)  aside  from extreme  conditions,  a
cut  off  at  median  percentage  of  positive  cells  can  be
reasonably used for evaluating the half of samples with higher
vs. the half of samples with lower VDR expression. Therefore,
results  were ranked based on percentage of  cells  positive  for
VDR  expression  (irrespective  of  staining  intensity).
Cytoplasmic VDR expression ranged from 0% to 100%, with
a median value at 20.0%. We categorized variables as follows:
100%  cytoplasmic  VDR-expression-positive  cells  versus  all
remaining  melanomas;  >20%  cytoplasmic  VDR-expression-
positive  cells  (high  VDR  expression)  vs.  ≤20%  positive  cells
(low  VDR  expression);  and  absent  (0%  positive  cells)  vs.
present (>0% positive cells) VDR expression. Only 11 out of
74  cases  (14.9%)  showed  nuclear  VDR-positive
immunostaining,  and  all  these  cases  were  categorized  into
>20%  cytoplasmic  VDR-expression-positive  cells.  Given  the
low  number  of  melanoma  specimens  showing  VDR
expression detected in nuclei, this parameter was not further
analyzed.
Determination of VDR gene polymorphisms
Determination of SNP VDR-FokI (C>T), VDR-BsmI (G>A),
VDR-ApaI  (T>G),  VDR-TaqI  (T>C)  was  performed  as
previously  described29,45  after  extraction  of  genomic  DNA
from  ethylenediaminetetraacetic-acid  -venous  blood  sam-
ples46. Absence or presence of restriction site was denoted by
a  capital  or  lower  letter,  respectively:  “F”  and  “f”  for  FokI,
“B” and “b” for BsmI, “A” and “a” for ApaI, and “T” and “t”
for  TaqI  endonucleases28,29.  FokI,  BsmI,  ApaI  and  TaqI
polymorphisms of VDR were studied using previously tested
primers29,45  to  amplify  appropriate  DNA  fragments.  FokI
enzyme  (Euroclone,  Milano,  Italy)  digestion  of  265  bp
amplified  DNA  was  used  to  determine  FokI  restriction
fragment  length  polymorphism  (RFLP)  yielding  196  and  69
bp  fragments  in  the  presence  of  f  allele46.  To  analyze  BsmI
polymorphism,  the  resulting  amplified  825  bp  polymerase
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chain  reaction  (PCR)  fragment  was  digested  with  BsmI
restriction enzyme (Euroclone, Milano, Italy), generating 650
and  175  bp  fragments  in  the  presence  of  b  allele29.  ApaI
digestion  of  the  740  bp  amplified  DNA  was  used  to
determine both ApaI and TaqI RFLP, generating 530 and 210
bp fragments in the presence of a allele. Digestion with TaqI
of the 740 bp PCR fragment generated 290, 245, and 205 bp
fragments  in  the  presence  of  t  allele  and  495  and  245  bp
fragments  in  its  absence  (T  allele)  owing  to  an  additional
monomorphic TaqI site29. DNA fragments were separated by
polyacrylamide gel electrophoresis.
Statistical analysis
Kolmogorov-Smirnov  test  was  used  to  assess  normal  data
distribution.  Percentage  of  VDR-positive  cells  by  immuno-
histochemical  staining  was  not  normally  distributed.  Thus,
median  values  and  ranges  were  reported  for  this  variable.
Mann-Whitney U test was used to assess differences between
groups.  Odds  ratios  (ORs)  and  95%  confidence  intervals
(CIs) were calculated to determine association of groups with
different  VDR  expression  and  melanoma  characteristics,
alleles,  genotypes,  and  combined  genotypes.  Our  study  was
explorative  as  no  previous  investigation  determined  fre-
quencies  of  VDR  polymorphisms  in  melanoma  patients
according  to  immunohistochemical  findings  of  VDR  expre-
ssion Prior  to  study enrolment,  we evaluated that  a  number
of 70 subjects fitted the 80% power at  an alpha level  of  0.05
to  detect  differences  between  high  (above  the  median)  and
low  VDR  expression  melanoma  groups  whether  OR  value
equals  3  or  more  for  a  SNP  site47.  Deviation  tests  from
Hardy-Weinberg  equilibrium (HWE)  were  performed  using
a  separate  Chi-square  distribution  for  each  SNP29.  Linkage
disequilibrium  (LD)  between  SNPs  was  determined  as
described29.  Two-sided significance level was set at 0.05, and
P  values  ≤  0.10  were  considered  as  a  tendency  to  be
significant.  Statistical  software SPSS (SPSS Inc.,  Chicago,  IL,
USA) was used for statistical analyses.
Results
VDR immunohistochemical staining
A significant variability in VDR immunohistochemical stain-
ing was observed in cytoplasm of melanoma cells, with 16.2%
(12/74)  of  patients  tested  positive  for  100%  melanoma  cell
staining, whereas 20.3% (15/74) were tested negative. Median
percentage  value  of  VDR-positive  staining  reached  20.0%.
Figures  1,  2,  and  3  display  representative  images  of  VDR
immunohistochemical  staining  in  excised  tissues  from
patients  with  primary  cutaneous  melanoma,  showing  100%
staining, intermediate staining, and no staining, respectively.
Patients and melanoma characteristics
according to VDR expression
All  74  (35  females  and  39  males)  cutaneous  melanoma
patients  were  white  residents  in  Northern Italy.  Average  age
at  melanoma  diagnosis  was  52.1±12.7  years,  with  27%
 
Figure 1     Representative image of VDR protein expression in
cutaneous melanoma tissue. Melanoma showing diffuse positivity
for VDR expression. Eroded epidermis (H&E staining, 25×. Bar
indicates 50 μm).
 
Figure 2     Representative image of VDR protein expression in
cutaneous  melanoma  tissue.  Melanoma  featuring  tumor-
infiltrating lymphocytes (TILs). Intraepidermal component of lesion
(at  the  bottom  of  image)  shows  strong  positivity  for  VDR
expression (H&E staining, 25×. Bar indicates 50 μm).
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(20/74)  of  patients  exhibiting  metastatic  melanoma  (i.e.,
stages  III  and  IV),  and  all  showed  Clark  level  higher  than
Clark I invasion.
Table  1  shows  the  main  clinical  characteristics  of
melanoma  patients  and  compares  three  different  binary
categories according to percentage of tumor cells positive for
VDR staining: a) 100% positive vs. <100% positive, b) over
20% (median value) positive (high VDR expression) vs.  ≤
20%  positive  (low  VDR  expression),  and  c)  absence  vs.
presence of VDR-positive cells. Complete data on ORs and
CIs are reported on Table S1. Age of melanoma diagnosis,
gender, BMI, and smoking did not differ between compared
groups. Differences were not significant in comparison of 12
subjects with 100% VDR-positive cells vs. 62 subjects with
<100%  VDR-positive  cells.  The  following  statically
significant differences were observed during comparison of
36 melanomas with high VDR expression vs. 38 melanomas
with low VDR expression: stage I was more frequent in the
former (63.9% vs. 39.5%, OR=2.71, CI=1.06–6.95, P=0.036),
whereas  stage  II  was  less  frequent  (11.1%  vs.  31.6%,
OR=0.27,  CI=0.08–0.94,  P=0.033);  the  former presents  a
lower mean Breslow thickness (1.23±0.88 vs. 2.27±1.97 mm,
P=0.008) and more frequent Breslow thickness of <1.00 mm
(50.0% vs. 26.3%, OR=2.80, CI=1.06–7.41, P=0.036) and less
frequent  Breslow  thickness  ≥1.01  mm  (50.0%  vs.  77.8%,
OR=0.36,  CI=0.13–0.95,  P=0.036).  A higher frequency of
Clark II invasion (38.9% vs. 15.8%, OR=3.39, CI=1.13–10.2,
P=0.025) was observed in high- than low-VDR-expression
group.  Superficial  spreading  was  present  in  61.1%  of
melanomas  with  high  VDR expression  vs.  39.5% of  low-
VDR-expression melanomas, where this difference did not
reach significant P values (P=0.063). In comparing absence
vs. presence of VDR-positive immunohistochemical staining
of melanoma cells, the only significant finding was a higher
frequency of stage II A in the former vs. the latter (26.7% vs.
5.1%, OR=6.79, CI=1.33–34.7, P=0.028) (all sub-stage data
are shown in Table S1).
Overall, as shown in Table 1, none of the tumor markers
commonly associated with severe prognosis and metastatic
stage  were  associated  with  VDR  immunohistochemical
staining;  these  markers  included  ulceration,  mitosis  >1,
absence of tumor-infiltrating lymphocytes (TILs), emboli,
and  epithelioid  variants.  The  presence  of  multiple
melanomas, additional skin, non-skin cancers, and melanoma
familiarity did not correlate with VDR immunohistochemical
staining.
By further analysis, median VDR expression did not differ
between 20 metastatic melanomas (median: 17.5%, range:
0%–100%  VDR-positive  cells)  and  54  non-metastatic
melanomas (median: 25.0%, range: 0%–100% VDR-positive
cells), with P=0.796. Significant P value (P=0.095) was not
observed in differences in median values of VDR expression
of  stage  I  melanomas  compared  with  those  of  stages
II+III+IV. Median values of VDR expression of Clark II (in
our cohort,  none of melanomas showed Clark I invasion)
melanomas were significantly higher compared with Clark
III+IV+V  levels  (median:  70.0%,  range:  0%–100%  vs.
median:  10.0%,  range:  0%–100%  VDR-positive  cells,
P=0.019).  A  significant  P  value  was  not  observed  in
differences  in  median  values  of  VDR  expression  in
superficially  spreading  melanomas  compared  with  the
remaining ones (P=0.075).
Patient and melanoma characteristics
according to VDR polymorphisms
Table  2  shows  VDR  polymorphism  genotypes,  alleles,  and
combined  genotype  frequencies  in  all  74  patients  and  in
groups  of  melanomas  categorized  according  to  VDR
immunohistochemical staining. Each VDR polymorphism of
FokI, BsmI, ApaI, and TaqI was in HWE. FokI SNP was not
in LD with other SNPs. BsmI was in LD with ApaI and TaqI,
and ApaI was in LD with TaqI. Thus, for further analyses, we
considered  binary  and  ternary  combination  of  genotypes
comprising  BsmI,  ApaI  and  TaqI  polymorphisms.  As
observed  in  other  studies26,29,  not  all  theoretically  possible
binary and ternary combination of genotypes were observed;
thus,  Table  2  reports  only combined genotypes  with at  least
one confirmed finding.
Differences  between  VDR  expression  groups  were  not
 
Figure 3     Representative image of VDR protein expression in
cutaneous melanoma tissue. Melanoma featuring TILs. In this case,
melanoma cells nesting in the dermis are negative throughout the
whole lesion (H&E staining, 25×. Bar indicates 50 μm).
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Table 2     Genotype and allele of  ApaI,  VDR-polymorphism, and BsmI-ApaI,  ApaI-TaqI,  BsmI-ApaI-TaqI  combined genotypes of  74
melanoma patients and comparisons between groups of 100% VDR-positive cells (n=12) vs. <100% (n=62); over the median (>20%) VDR-
positive cells (n=36) vs. below or equal the median (≤20%) (n=38); and absence of VDR-positive cell (n=15) vs. remaining cases with
detected VDR expression (n=59).
VDR
genotype
or
combined
genotype
All
melanoma
patients
(n=74)
100%
VDR-
positive
cells
(n=12)
<100%
VDR-
positive
cells
(n=62)
P=100%
vs.<100%
VDR-
positive
>20%a
VDR-
positive
cells
(n=36)
≤20%
VDR-
positive
cells
(n=38)
P>20% vs.
≤20%
VDR-
positive
VDR
absence
(0%
positive)
(n=15)
VDR
presence
(>0%
positive)
(n=59)
PVDR
absence
vs.
presence
ApaI genotype
AA 30 (40.5) 8 (66.7) 22 (35.5) 0.058 13 (36.1) 17 (44.7) 0.450 8 (53.3) 22 (37.3) 0.258
Aa 36 (48.6) 4 (33.3) 32 (51.6) 0.246 22 (61.1) 14 (36.8) 0.037 5 (33.3) 31 (52.5) 0.184
aa 8 (10.8) 0 (–) 8 (12.9) 0.339 1 (2.8) 7 (18.4) 0.056^ 2 (13.3) 6 (10.2) 0.660
A allele 96/148
(64.9)
20/24
(83.3)
76/124
(61.3)
0.038 48/72
(66.7)
48/76
(63.2)
0.655 21/30
(70.0)
75/118
(63.6)
0.509
a allele 52/148
(35.1)
4/24
(16.7)
48/124
(38.7)
0.038 24/72
(33.3)
28/76
(36.8)
0.655  9/30
(30.0)
43/118
(36.4)
0.509
BsmI-ApaI combined genotype
BBAA 23 (31.1) 5 (41.7) 18 (29.0) 0.498 9 (25.0) 14 (36.8) 0.271 6 (40.0) 17 (28.8) 0.533
BbAA 5 (6.8) 3 (25.0) 2 (3.2) 0.028 4 (11.1) 1 (2.6) 0.194 1 (6.7) 4 (6.8) 1.000
BbAa 31 (41.9) 1 (8.3) 30 (48.4) 0.010 18 (50.0) 13 (34.2) 0.169 5 (33.3) 26 (44.1) 0.452
Bbaa 2 (2.7) 0 (–) 2 (3.2) 1.000 0 (–) 2 (5.3) 0.494 0 (–) 2 (3.4) 1.000
bbAA 2 (2.7) 0 (–) 2 (3.2) 1.000 0 (–) 2 (5.3) 0.494 1 (6.7) 1 (1.7) 0.367
bbAa 5 (6.8) 3 (25.0) 2 (3.2) 0.028 4 (11.1) 1 (2.6) 0.194 0 (–) 5 (8.5) 0.576
bbaa 6 (8.1) 0 (–) 6 (9.7) 0.581 1 (2.8) 5 (13.2) 0.200 2 (13.3) 4 (6.8) 0.595
ApaI-TaqI combined genotype
AATT 4 (5.4) 0 (–) 4 (6.5) 1.000 0 (–) 4 (10.5) 0.115 3 (20.0) 1 (1.7) 0.025
AATt 14 (18.9) 6 (50.0) 8 (12.9) 0.008 9 (25.0) 5 (13.2) 0.194 4 (26.7) 10 (16.9) 0.463
AAtt 12 (16.2) 2 (16.7) 10 (16.1) 1.000 4 (11.1) 8 (21.1) 0.246 1 (6.7) 11 (18.6) 0.439
AaTT 12 (16.2) 3 (25.0) 9 (14.5) 0.399 9 (25.0) 3 (7.9) 0.046 1 (6.7) 11 (18.6) 0.439
AaTt 24 (32.4) 1 (8.3) 23 (37.1) 0.089 13 (36.1) 11 (28.9) 0.511 4 (26.7) 20 (33.9) 0.761
aaTT 8 (10.8) 0 (–) 8 (12.9) 0.339 1 (2.8) 7 (18.4) 0.056^ 2 (13.3) 6 (10.2) 0.660
BsmI-ApaI-TaqI combined genotype
BBAATT 1 (1.4) 0 (–) 1 (1.6) 1.000 0 (–) 1 (2.6) 1.000 1 (6.7) 0 (–) 0.203
BBAATt 10 (13.5) 3 (25.0) 7 (11.3) 0.351 5 (13.9) 5 (13.2) 1.000 4 (26.7) 6 (10.2) 0.110
BBAAtt 12 (16.2) 2 (16.7) 10 (16.1) 1.000 4 (11.1) 8 (21.1) 0.246 1 (6.7) 11 (18.6) 0.439
BbAATt 4 (5.4) 3 (25.0) 1 (1.6) 0.012 4 (11.1) 0 (–) 0.051 0 (–) 4 (6.8) 0.576
BbAATT 1 (1.4) 0 (–) 1 (1.6) 1.000 0 (–) 1 (2.6) 1.000 1 (6.7) 0 (–) 0.203
BbAaTT 7 (9.5) 0 (–) 7 (11.3) 0.590 5 (13.9) 2 (5.3) 0.255 1 (6.7) 6 (10.2) 1.000
BbAaTt 24 (32.4) 1 (8.3) 23 (37.1) 0.089 13 (36.1) 11 (28.9) 0.511 4 (26.7) 20 (33.9) 0.761
BbaaTT 2 (2.7) 0 (–) 2 (3.2) 1.000 0 (–) 2 (5.3) 0.494 0 (–) 2 (3.4) 1.000
bbAATT 2 (2.7) 0 (–) 2 (3.2) 1.000 0 (–) 2 (5.3) 0.494 1 (6.7) 1 (1.7) 0.367
bbAaTT 5 (6.8) 3 (25.0) 2 (3.2) 0.028 4 (11.1) 1 (2.6) 0.194 0 (–) 5 (8.5) 0.576
bbaaTT 6 (8.1) 0 (–) 6 (9.7) 0.581 1 (2.8) 5 (13.2) 0.200 2 (13.3) 4 (6.8) 0.595
a Over the median value of percentage (%) of cells positive for VDR protein. b OR uncountable because one or two of compared groups
included zero subject. c P value by Mann–Whitney U test.
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significant for single FokI,  BsmI, and TaqI genotypes and
alleles, and BsmI-TaqI combined genotypes (data shown in
Table S3).
As reported in Table 2 (data comprising all ORs and CIs
are  shown  in  Table  S2.  Table  S1  to  Table  S3  in  the
supplementary materials, available with the full text of this
article at www.cancerbiomed.org), heterozygous Aa genotype
was more frequent in melanomas with high than low VDR
expression  (61.1%  vs.  36.8%,  OR=2.69,  CI=1.05–6.90,
P=0.037). A allele was found in 83.3% of 100% VDR-positive
melanomas and in 61.3% of those with <100% VDR-positive
cells (OR=3.16, CI=1.02–9.80, P=0.038).
By analyzing combined genotypes (Table 2), six significant
differences were observed after comparing 100% vs. <100%
VDR-expression-positive  groups.  Combined  genotypes
BbAA (OR=10.0, CI=1.46–68.3, P=0.028), bbAa (OR=10.0,
CI=1.46–68.3,  P=0.028),  AATt  (OR=6.75,  CI=1.74–26.1,
P=0.008), BbAATt (OR=20.3, CI=1.90–217, P=0.012), and
bbAaTT  (OR=10.0,  CI=1.46–68.3,  P=0.028)  were  more
frequent in the former vs. the latter group, whereas combined
genotype BbAa (OR=0.10, CI=0.01–0.80, P=0.010) was less
frequent in the former group than the latter.
In  comparing  the  >20%  vs.  ≤20%  VDR-expression-
positive groups, combined genotype AaTT (OR=3.89, CI=
0.96–15.8, P=0.046) was more frequent in the former than in
the latter group.
In comparing absent- vs. present-VDR-expression groups,
the  ApaI-TaqI  combined  genotype  AATT  (OR=14.5,
CI=1.39–152, P=0.025) was more frequent in the melanoma
group lacking VDR expression vs. the remaining patients.
Considering  continuous  median  percentage  values  of
VDR-expression-positive  cells,  with  100%  VDR-positive
cells, significantly higher VDR expression was observed for
bbAa  (median:  100.0%,  range:  15%–100%  vs.  median:
20.0%,  range:  0%–100%,  P=0.029),  BbAATt  (median:
100.0%,  range:  60%–100%  vs.  median:  20.0%,  range:
0%–100%,  P=0.011),  bbAaTT  (median:  100.0%,  range:
15%–100% vs. median: 20.0%, range: 0%–100%, P=0.029)
combined genotype carriers  vs.  non-carriers.  By contrast,
significantly lower VDR expression was noted for carriers of
AATT combined genotype (median: 0.0%, range: 0%–10%
vs.  median;  30.0%,  range:  0%–100%,  P=0.014)  vs.  non-
carriers.
Discussion
In our study, VDR expression was predominantly assessed in
cytoplasm of  melanoma cells  (79.7%,  59/74 cases),  with  few
tumors (14.9%, 11/74 cases) displaying VDR positivity in the
nucleus.  Such  findings  partially  contrast  those  of  other
studies  performed  in  a  Polish  cohort  of  69  patients  with
primary  cutaneous  melanoma  (comprising  35  metastatic
melanomas  and  that  were  classified  as  follows:  4  Clark  I,  6
Clark  II,  23  Clark  III,  24  Clark  IV,  and  12  Clark  V  stage,
where  30  were  superficial-spreading,  37  were  nodular,  and
two  were  acral  lentiginous  melanomas);  these  previous
studies  indicated  VDR-positive  nuclear  immunostaining  in
84.1%  and  cytoplasmic  immunostaining  in  66.7%  of
patients38,39.  The study by Brożyna et al.39,  however, showed
percentage  of  melanoma  specimens  with  high  nuclear
staining at 17.4% (12/69), which is close to the percentage of
nuclear  staining  in  our  study.  Discrepancies  between  results
of Brożyna et al. and our study probably arise from different
antibodies  employed21,  diverse  histological  characteristics,
and/or  geographical/genetic  backgrounds  of  melanomas  in
the  respective  studies.  According  to  European  cancer
observatory data3, the estimated age standardized (European)
incidence  rate  (per  100,000/year)  of  malignant  cutaneous
melanoma and mortality are 5.6 and 2.8 in Poland and 13.4
and 2.0 in Italy, respectively.
We  further  analyzed  data  regarding  cytoplasmic  VDR
immunohistochemical staining. Once the cytoplasmic VDR
binds with 1α, 25-dihydroxyvitamin D ligand, and adequate
coreceptor protein, retinoid X receptor, it translocates to the
nucleus, and by recruitment of coactivators and corepressors
modulates transcription of target genes that encode proteins
responsible  for  final  activities  induced  by  vitamin  D
hormonal  signaling18.  Consequently,  absence  or  down-
regulation of VDR expression may present implications for
vitamin  D  resistance  in  melanoma  tissues38,48,49  and
potentially modulates effects of vitamin D supplementation
on prevention therapy of melanoma patients49,50.
We did not observe effects of age at melanoma diagnosis
and gender on VDR expression in cutaneous melanomas45.
Roles  of  BMI  and  smoking  were  focuses  of  previous
melanoma research8,25,51. In the present investigation, we did
not  observe  the  effects  of  BMI  and  smoking  on  VDR
expression.
Consistent with studies performed by other authors on a
Polish cohort38,39, we observed that stage I melanomas were
more  frequent  in  tumors  with  high  than  with  low  VDR
expression. In our study, stage IIA invasion was particularly
more frequent in melanomas lacking VDR expression than in
melanomas showing VDR expression. However, we did not
observe significant data in relation to metastatic stages III
and IV. Causes of these findings will require further enlarged
studies.
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Overall,  metastatic melanomas did not exhibit different
VDR  expression  from  non-metastatic  melanomas.  Such
results agreed with observations of some studies13,20,48  but
contradicted  the  findings  of  other  authors38,39.  Specific
geographical/ethnic backgrounds possibly affected results.
Thus, enlarged studies in subjects with different ethnicities
should be performed in the future to substantiate this issue.
In our study, localization of melanoma on the body was
unrelated  with  VDR  expression.  We  only  observed  a
tendency (P=0.093) for upper limb melanomas to be more
frequent in tumors lacking VDR expression. Thus, despite
the  expected  different  exposures  to  sunlight  and
environmental factors of different parts of the human body,
VDR expression in our study is  not  associated with body
regions in which primary melanomas develop.
Lesion-specific characteristics did not correlate with VDR
expression; these characteristics include ulceration, number
of mitotic figures, regression, absence of TILs, non-brisk or
brisk  TILs,  tumor  emboli,  and  melanoma  subtype
(epithelioid and small cell). At variance, in Polish patients
studied  by  Brożyna  and  colleagues39  cytoplasmic  VDR
immunostaining was higher in group of brisk TIL-positive vs.
that of absent and non-brisk TIL melanomas (P=0.01), and
VDR expression was lower in melanomas with ulceration.
We noted  a  tendency  for  higher  frequency  of  superficial
spreading (P=0.063) in melanomas with high than low VDR
expression.  Similarly,  Brożyna  and colleagues38  observed
higher  VDR  expression  in  superficially  spreading  than
nodular melanomas.
Remarkably,  VDR  expression  was  related  to  tumor
Breslow thickness and Clark levels  in our Italian patients.
Melanomas  with  a  thickness  below  1.00  mm  were  more
frequently  observed  in  cases  with  high  than  low  VDR
expression, whereas those with thickness of over or equal to
1.01 mm were more frequent in melanomas with low VDR
expression. Clark level II (none of the studied melanomas
presented  a  Clark  I)  was  detected  more  frequently  in
melanomas with high than low VDR expression (P=0.025).
Overall, such findings concur with previous data on Polish
patients38,39.
We observed that VDR expression was unrelated with the
presence of multiple melanomas, additional non-melanoma
skin  cancers  and  non-skin  cancers,  and  melanoma
familiarity. To our knowledge, no previous study assessed
these issues.
To our knowledge, our study was the first to investigate
the  relationship  between  VDR  expression  of  human
melanoma  cells  in  excised  tissues  of  patients  and  VDR
polymorphisms.  Out  of  four  VDR  polymorphisms
investigated in our study, individual SNPs of FokI, BsmI, and
TaqI did not display any relation with expression of VDR in
melanoma. Only the ApaI genotype was correlated to VDR
expression in melanoma. The heterozygous genotype Aa was
identified in 61.1% of melanomas with high VDR expression
vs. 36.8% of melanomas with low VDR expression (OR=2.69,
P=0.037). A allele was more frequent in 100% than <100%
VDR-positive cells (OR=3.16, P=0.038). To our knowledge,
no research studied the role of VDR-ApaI polymorphism in
VDR expression  in  melanoma tissues.  VDR-ApaI  SNP is
located  in  an  intron  sequence  and  thus  cannot  directly
modify the amino acid sequence of VDR protein; however, it
participates  in  VDR  RNA  processing26.  Recent  evidence
demonstrated  that  intronic  sites  of  the  VDR  gene  can
function as binding sites of transcriptional regulators, such as
p5352,53.  A meta-analysis study35  indicated that VDR-ApaI
polymorphism  of  the  European  population  features  an
association with overall skin cancer risk (Aa vs. AA, OR=1.27,
CI=1.05–1.53; Aa+aa vs. AA, OR=1.23, CI=1.04–1.47). In a
recent  Italian  study,  the  Aa  heterozygous  genotype  was
associated  with  increased  risk  of  lumbar  pathologies,
especially osteochondrosis29.
A number of  combined genotypes in our study yielded
significant findings according to VDR expression. The AaTT
combined genotype was more frequent in melanomas with
high than low VDR expression. Combined genotypes BbAA,
bbAa, AATt, BbAATt, and bbAaTT were more frequent in
100% VDR-positive cells  than <100% VDR-positive cells.
The AATT combined genotype was much more frequent in
subjects without VDR expression (20%) than in those with
VDR expression (1.7%) (OR=14.5, P=0.025). No previous
study investigated the relationship of VDR expression with
VDR  combined  genotypes.  Lack  of  VDR  expression  in
excised melanoma tissues has been associated with reduced
overall  survival  of  patients38,39.  Therefore,  melanoma
prognosis may be influenced by carrying a VDR combined
genotype associated to absent or reduced VDR expression. In
our melanoma patients, AATT is a rare combined genotype
with  a  frequency  of  5.4%,  which  is  similar  to  the  recent
finding in an Italian cohort of 518 non-oncological subjects
(6.0%)29.  Further enlarged studies are warranted to assess
roles of ApaI, BsmI, and TaqI combined genotypes in VDR
expression in melanomas and their prognosis.
Regulation of VDR abundance is an important modulation
mechanism  of  cel lular  responsiveness  to  1α ,  25-
dihydroxyvitamin D10. Mechanisms underlying regulation of
VDR abundance include alterations in transcription rate of
VDR gene and/or stability  of  VDR mRNA and epigenetic
changes14,18,54.  Interestingly,  treatment with calcitriol  can
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enhance VDR mRNA in cultured melanoma cells, showing
that  increasing  vitamin D consumption can induce  VDR
expression14.  On the other hand, enhanced melanogenesis
was  associated  with  downregulation  of  VDR  ex-
pression38,55,56.  Response  of  melanoma  cells  to  calcitriol
corresponds to expression level  of  VDR mRNA, which in
turn may be regulated by VDR miRNAs and by epigenetically
modulating drugs50.  Remarkably, recent evidence suggests
that tumor suppressors, such as p53, are implicated on direct
regulation of VDR53. Molecules other than vitamin D, such
as curcumin and vitamin E derivatives,  were indicated as
novel VDR ligands19,57, whereas vitamin A derivatives were
suggested as modulators of VDR actions58. Given the wide
variety  of  positive  and  negative  VDR  modulators,  each
individual expression of VDR is highly dynamic in cells, with
nuclear  translocation  of  VDR  fluctuating  upon  instant
induction18,19,22. We speculate that unresponsiveness of some
cutaneous melanomas to anti-proliferative effects of vitamin
D  possibly  resulted  from  absence  or  insufficient  VDR
expression in melanoma and/or melanocytic cells. Further
human studies are warranted to assess whether benefits of
vitamin D augmentation are modulated by VDR expression
in  melanoma/melanocytic  cells  and/or  by  carriage  of  a
specific  VDR  genotype  and/or  combined  genotype
polymorphisms that affect VDR expression. Such factors can
modulate dose requirement of vitamin D treatments59.
Roles of vitamin D in skin cancers still require complete
elucidation10,57. All vitamin D actions virtually occur through
VDR activation. Recent evidence shows that the effects of 1α,
25-dihydroxyvitamin D and VDR are mediated at least in
part  by  cellular  calcium  levels;  thus,  calcium  possibly
contributes  to  the  suppressive  ability  of  VDR  on  skin
cancer10,57. Deletion of VDR notably results in an increased
susceptibility to tumorigenesis  and also reduces ability of
keratinocytes to clear UVB-induced DNA mutations57. VDR
can bind to thousands of VDREs on human genome and up-
or  downregulate  hundreds  of  genes10,30,57.  Based  on
bioinformatic analysis, almost 15,000 sites in human DNA
are bound by VDR, and 16%–21% of these putative binding
sites are found at gene promoters10,57,60. Aside from classical
VDRE-mediated mechanisms, increasing evidence point to
regulatory contribution of several miRNAs14,18,54  and long
non-coding  RNAs10,57.  A  recent  study  on  VDR  cistrome
demonstrated the unexpected complexity of gene regulation,
which was examined on a genome-wide scale in target tissues
and cells, including a cross-talk between VDR and immune
factors60,61.  VDR  expression  is  also  commonly  and
significantly down regulated in colon adenocarcinoma. VDR
cistrome analyses suggested that reduced VDR expression in
colon cancer changes VDR activity by dampening expression
of tumor suppressors by either stabilizing or inhibiting down
regulation of oncogene expression. In turn, these effects may
be associated with severe patient outcomes62. Thus, further
research  should  study  complex  gene  interactions  and
biological pathways related to vitamin D and melanoma and
combine clinical evidence with molecular findings to support
further progress57,60,61.
Limitations of our study include the limited number of
patients and absence of data on circulating vitamin D levels
in patients at the time of melanoma excision. Strengths of
this  research comprise genetic  background restrictions of
enrolled  patients  and  determination  of  demographic,
lifestyle, histological, and genetic characteristics.
Given the sample size and multiple comparisons of our
study,  a  validation  of  independent  datasets  with  larger
samples, and multivariable analysis will be necessary to adjust
genetic traits for age, sex, tumor location, sun exposure, and
smoking.  Serum  sampling  in  future  studies  may  also  be
performed to determine circulating levels of vitamin D at
time of melanoma excision.
Conclusions
Current  information  insufficiently  discusses  influence  of
vitamin  D  oral  supplementation  to  direct  VDR  modulatory
effects  in  human  skin  cells,  including  melanocytes  and
keratinocytes.  Our  present  findings  support  the  necessity  of
further  studies  on  this  issue  by  combining  clinical  and
molecular approach.
Our study showed that VDR expression is associated with
prognostic parameters of tumor Breslow thickness and Clark
level. However, VDR expression was not related to metastatic
melanomas. Our immunohistochemical results concur with
those of a previous study on VDR expression in colorectal
cancer,  showing that VDR was not associated with tumor
location, stage, and grade42,  and with another lung tumor
study  which  demonstrated  high  variability  of  VDR
expression43. Interestingly, we observed correlation between
the Aa genotype and AaTT combined genotype with higher
level  of  VDR  expression  and  between  AATT  combined
genotype and low or absent VDR expression; this new finding
will require further validation. Future studies should assess
whether  VDR  expression  and  VDR  combined  genotypes
affect  benefits  of  vitamin D and can drive an appropriate
dose and schedule of calcitriol or other active (low calcemic)
vitamin D analogs for melanoma treatment. Future set up of
personalized  nutrition  and  behavioral  interventions  will
benefit from molecular studies exploring the connection of
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biological  pathways to bioactive components of  food and
cancer63.  Our  study  suggests  that  determination  of  VDR
expression  in  excised  tissues  of  melanoma  and/or
determination of  VDR  genotypes  carriage  can be  used as
personalized tool of precision medicine when considering
melanoma patients.
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